In dialysis-dependent patients, those on denosumab for fracture risk had a 36% higher MACE rate than those on bisphosphonates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback